What Chiome Bioscience does

Chiome Bioscience Inc. is a Tokyo-based clinical-stage biotechnology company (TSE Growth Market, ticker 4583; founded February 2005) that discovers and develops therapeutic antibody candidates and out-licenses them to pharmaceutical companies for clinical and commercial progression. Its proprietary ADLib® platform generates monoclonal antibodies in vitro using DT40 chicken B cells activated by Trichostatin A, enabling antigen-specific clone selection in approximately 10 days without animal immunization. The company has extended this core into a Human ADLib® system (genetically modified DT40 cells producing human antibodies directly, granted in Japan, Europe, and China) and the Tribody™ multi-specific antibody platform (acquired from Biotecnol Limited in December 2018), the latter yielding CBA-1535, the world's first trispecific antibody in clinical development. Supporting capabilities include ADLib® Affinity Maturation (KI-AMP), protein expression and purification, stable cell line development, and IgM purification, plus the ATAC® amatoxin-payload ADC technology introduced from Heidelberg Pharma in July 2022.

The clinical-stage pipeline includes CBA-1205 (ADCC-enhanced anti-DLK-1 antibody, Phase 1) and CBA-1535 (Tribody™ 5T4×CD3, Phase 1). Earlier-stage and out-licensed assets cover ADCT-701 (LIV-1205 ADC with PBD payload, Phase 1 via NCI/ADC Therapeutics, first patient dosed July 2024), PCDC (anti-CDCP1 ADC), PTRY (5T4×CD3×PD-L1 multi-specific), BMAA (anti-Semaphorin 3A), LIV-2008/2008b (anti-TROP-2, previously licensed to Shanghai Henlius until January 2023), PFKR (anti-CX3CR1, out-licensed to Asahi Kasei Pharma for SPMS), and PXLR (anti-CXCL1/2/3/5).

The company operates two business segments. The primary growth driver is Drug Discovery and Development, which generates upfront signing fees, development milestone payments (tied to IND filing and Phase transitions), and royalties on net sales from out-licensed candidates. The second segment is Drug Discovery Support Services, which provides antibody generation using ADLib®/hybridoma/B cell cloning, protein expression and purification, and stable cell line development on a fee-for-service, project-by-project basis to pharmaceutical companies, diagnostic companies, and academic/research institutions globally. Service revenue is reported as ¥210M (2018), ¥420M (2019), and ¥480M (2020), with continued growth since 2020; pricing is custom and not publicly disclosed. Distribution is direct, consultative, and technically-led, executed by PhD-qualified staff from initial inquiry through project delivery.

Name

Chiome Bioscience

Legal name

株式会社カイオム・바이오サイエンス

Website

https://chiome.co.jp

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

Chiome Bioscience is a Tokyo-based clinical-stage biotechnology company that develops and out-licenses therapeutic antibody candidates using its proprietary ADLib® in vitro antibody platform, while offering antibody generation and protein engineering services to pharmaceutical, diagnostic, and research clients globally.

Ownership category

akta.pro rank

Product category

Therapeutic Antibody Discovery & Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• Therapeutic antibody discovery
• Monoclonal antibody services
• Antibody drug development
• Biotech contract research
• ADC development

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Discovery and Development (Out-licensing): Chiome develops antibody drug candidates from basic/exploratory research through preclinical stage and out-licenses them to pharmaceutical companies. Revenue comes from upfront signing fees, development milestone payments tied to progress (e.g., IND filing, Phase transitions), and royalty payments on net sales if the product reaches market. This is the primary growth driver.
2. Drug Discovery Support Services (Contract/Fee-for-service): Chiome provides antibody generation services (using ADLib® system, hybridoma, B cell cloning) and recombinant protein preparation/purification services to pharmaceutical companies, diagnostic companies, and academic/research institutions on a fee-for-service basis. Services can be individual project-based, comprehensive contracts, or collaborative research agreements. Revenue from this segment has been growing (from ¥210M in 2018 to ¥480M in 2020).

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Chiome Bioscience operates two integrated business segments: (1) Drug Discovery and Development — proprietary antibody drug candidates (including CBA-1205, CBA-1535, PCDC, and others) developed from basic research through preclinical stage and out-licensed to pharmaceutical companies for upfront fees, milestones, and royalties; and (2) Drug Discovery Support Services — fee-for-service antibody generation using the proprietary ADLib® system, hybridoma, and B cell cloning, plus recombinant protein expression/purification and stable cell line development for pharmaceutical companies, diagnostic firms, and academic research institutions.

Product overview

Chiome Bioscience operates two main business segments: (1) Drug Discovery and Development Business - developing therapeutic antibody candidates for out-licensing to pharmaceutical companies, with pipeline products including CBA-1205 (Phase 1, anti-DLK-1 for liver/lung cancer), CBA-1535 (Phase 1, Tribody™ trispecific for solid tumors), PCDC (ADC candidate, anti-CDCP1), and other pipeline candidates targeting TROP-2, Semaphorin3A, and CX3CR1; and (2) Drug Discovery Support Business - providing contract services including antibody generation using the proprietary ADLib® system, protein expression/purification, and stable cell line development to pharmaceutical companies, diagnostic companies, and research institutions. The company's core technology is the ADLib® system, a monoclonal antibody generation platform that does not require animal immunization.

Differentiator

Problem solved

Functional benefit

Brands

• ADLib® System: Proprietary monoclonal antibody generation technology using DT40 chicken B cells for rapid in vitro antibody discovery without animal immunization.
• Human ADLib® System
• Tribody™
• ADLib® Affinity Maturation (KI-AMP)

Products and services

• CBA-1205 (ADCC enhanced anti-DLK-1 antibody) ADCC-enhanced humanized anti-DLK-1 monoclonal antibody for cancer treatment; first-in-class therapeutic antibody targeting hepatocellular carcinoma, lung cancer, and neuroblastoma; currently in Phase 1 clinical trial in Japan.
• CBA-1535 (Tribody™ anti-5T4×CD3) Humanized trispecific anti-5T4×CD3 antibody (Tribody™) for cancer treatment; world's first Tribody™ format in clinical trials targeting malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and TNBC.
• PCDC (anti-CDCP1 antibody ADC candidate) Humanized anti-CDCP1 monoclonal antibody being developed as an antibody-drug conjugate with amatoxin payload (ATAC®); first-in-class therapeutic target for solid tumors including lung, colorectal, pancreatic, breast, and ovarian cancers; available for licensing.
• PTRY (5T4×CD3×PD-L1 Tribody™) Humanized multi-specific antibody using Tribody™ technology recognizing three molecules (5T4×CD3×PD-L1) for cancer immunotherapy targeting malignant mesothelioma, lung cancer, and TNBC; preclinical pipeline candidate with patent application.
• BMAA (anti-Semaphorin 3A antibody) Humanized anti-Semaphorin 3A antibody developed using ADLib® system for renal and other diseases; collaboration with Yokohama City University; available for licensing.
• LIV-2008/2008b (anti-TROP-2 antibody) Humanized anti-TROP-2 monoclonal antibody for cancer treatment; best-in-class therapeutic antibody targeting breast cancer (TNBC), lung cancer, and colorectal cancer; available for licensing.
• PFKR (anti-CX3CR1 antibody) Humanized anti-CX3CR1 antibody for autoimmune neurological diseases; functional inhibitory antibody targeting the Fractalkine (CX3CL1) receptor for secondary progressive multiple sclerosis (SPMS); licensed to Asahi Kasei Pharma.
• PXLR (anti-CXCL1/2/3/5 antibody) Humanized antibody targeting CXCL1/2/3/5 chemokines for cancer treatment; improves drug-resistant cancer microenvironment by reducing immunosuppressor cells in solid tumors; available for licensing.
• ADCT-701 (LIV-1205 ADC) Antibody-drug conjugate of Chiome's LIV-1205 anti-DLK-1 antibody with PBD (pyrrolobenzodiazepine) payload, targeting DLK-1 for solid tumors including neuroendocrine tumors; Phase 1 conducted by the National Cancer Institute (NCI) under license to ADC Therapeutics SA.
• ADLib® System Antibody Generation Services Monoclonal antibody generation services using the proprietary ADLib® system, including antigen-specific antibody generation and affinity maturation (KI-AMP); supports therapeutic antibodies, in vitro diagnostics, and life science research for pharmaceutical companies, diagnostic companies, and research institutions.
• Protein Expression and Purification Service Recombinant protein (antigen) expression and purification services including endotoxin-free plasmid isolation, transient mammalian cell expression, customizable purification, and protein analytics including membrane proteins.
• Stable Cell Line Development Service Stable cell line generation services for recombinant protein and antibody production using recombinant DNA technology for efficient expression.

Quantifiable outcome

• CBA-1205 Phase 1 first-in-human trial (AACR 2023): No dose-limiting toxicities or Grade 3+ serious adverse events across 7 cohorts (0.1–30mg/kg). 8 of 22 patients showed stable disease (SD). Long-term SD in melanoma (80 weeks), thymoma (39 weeks), pancreatic cancer (41 weeks). Partial response (PR) confirmed in 1 patient.
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

14 partnerships are on record, tiered major, core and minor.

• Heidelberg Pharma AGmajorTechnology or Integration · 1 July 2022Chiome introduced the ATAC®Platform technology from Heidelberg Pharma AG (Germany) for use with PCDC (anti-CDCP1 antibody ADC). The technology uses amatoxin (mushroom-derived toxin) as a cytotoxic payload, enabling enhanced cell-killing potency. The technology was applied to PCDC ADC for solid tumors (lung, colorectal, pancreatic, breast, ovarian).
• Shanghai Henlius BiotechmajorTechnology or Integration · 1 January 2021Chiome executed a license agreement with Shanghai Henlius Biotech (China) for the development, manufacture, and commercialization of anti-TROP-2 antibodies LIV-2008/2008b in China. The license agreement ended in January 2023.
• Biotecnol LimitedcoreTechnology or Integration · 1 December 2018Chiome executed an Asset Purchase Agreement to acquire Tb535H (now CBA-1535), a tri-specific (Tribody™) cancer therapeutic antibody, and the Tribody™ multispecific antibody technology platform. This acquisition provided Chiome with its second clinical-stage asset and a platform for generating additional multi-specific antibody candidates.
• ADC Therapeutics SAcoreTechnology or Integration · 1 September 2017Chiome executed a license agreement with ADC Therapeutics SA (Switzerland) for the development, manufacture, and commercialization of an ADC of LIV-1205 (the company's anti-DLK-1 antibody). Development code assigned is ADCT-701. NCI filed IND in the US, and first patient dosing for neuroendocrine tumors began in July 2024.
• RIKEN (理化学研究所)coreTechnology or Integration · 1 July 2005Chiome obtained an exclusive license from RIKEN and the Japan Science and Technology Agency (JST) to commercialize the ADLib® system platform technology, with sublicensing rights to third parties. In 2010, Chiome concluded a payment-based technology transfer agreement with JST for the ADLib® system patent. The technology was originally developed by Dr. Kunihiro Ohta at RIKEN.
• ProBioGen AGmajorTechnology or IntegrationProBioGen AG (Germany, Berlin) co-developed the manufacturing process for CBA-1205 clinical drug substance with Chiome. The collaboration included application of ProBioGen's GlymaxX® glycan modification technology for ADCC enhancement. CBA-1205 is manufactured using a standard monoclonal antibody process (cell culture, purification, formulation) with a proprietary hydrophobic interaction chromatography step.
• National Cancer Institute (NCI)coreStrategic or Co-development PartnerNCI (USA) completed IND submission in the US for ADCT-701 (LIV-1205 ADC), and the first patient dosing for neuroendocrine tumors (Phase 1) started in July 2024. ADCT-701 is an ADC combining Chiome's LIV-1205 anti-DLK-1 antibody with PBD (pyrrolobenzodiazepine) payload.
• The University of TokyomajorStrategic or Co-development PartnerJoint research with the University of Tokyo to scientifically validate and evaluate the practical utility of the Human ADLib® system. Results of this collaboration were published in Cellular & Molecular Immunology in 2020, demonstrating the system's utility for antibody drug discovery.
• National Center of Neurology and Psychiatry (NCNP)majorStrategic or Co-development PartnerNCNP collaborated with Chiome on the development of PFKR (humanized anti-CX3CR1 antibody) for the treatment of secondary progressive multiple sclerosis (SPMS) and other autoimmune neurological diseases. PFKR has been out-licensed to Asahi Kasei Pharma.
• Yokohama City University (Professor Yoshio Goshima)majorStrategic or Co-development PartnerThrough joint research with Professor Yoshio Goshima at Yokohama City University, Chiome established BMAA — a humanized anti-Semaphorin 3A antibody demonstrating both selectivity and functional inhibitory activity. Research published in Scientific Reports (2019) showed the antibody promotes nerve regeneration in early-stage peripheral nerve injury models.
• Osaka Metropolitan UniversityminorStrategic or Co-development PartnerOsaka Metropolitan University collaborated with Chiome on the development of PXLR (humanized anti-CXCL1/2/3/5 antibody) for the improvement of drug-resistant cancer microenvironments in solid tumors.
• Ceinge-Biotecnologie Avanzate (Italy)majorStrategic or Co-development PartnerChiome collaborated with Ceinge (Naples, Italy) on cancer immunotherapy research using Tribody™ technology. Joint research generated data on tribody constructs combining 5T4×CD3 with immune checkpoint molecules (PD-1, LAG-3, PD-L1), published in Journal of Experimental & Clinical Cancer Research in 2022.
• Niigata UniversityminorStrategic or Co-development PartnerNiigata University published research in Scientific Reports (2019) on the role of Semaphorin 3A in early-stage peripheral nerve regeneration using Chiome's anti-Semaphorin 3A antibody, demonstrating that antibody-mediated inhibition of SEMA3A promoted nerve regeneration at the site of injury.
• Asahi Kasei PharmacoreTechnology or IntegrationPFKR (humanized anti-CX3CR1 antibody) has been out-licensed to Asahi Kasei Pharma for the treatment of autoimmune neurological diseases including secondary progressive multiple sclerosis (SPMS). PFKR is a functional inhibitory antibody targeting the Fractalkine (CX3CL1) receptor.

Scale indicators4 records

Recent moves10 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/chiome-bioscience-inc-4583-

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chiome Bioscience